Challenge yourself after cancer by building healthier habits, strengthening relationships, managing stress and embracing new experiences for a healthier life.
|Articles|February 13, 2022
The Cancer Caregiver’s Pledge
Author(s)Ron Cooper
Here is a poem for cancer caregivers, who sacrifice their time with compassion and devotion to do everything they can to help an individual with cancer.
Advertisement
I pledge my unwavering devotion to your well-being.
I will strive hard to keep you stress-free.
I will try to convert chaos to calm on your worst days.
I will help you find strength of purpose on your best days.
I pledge patience as you express deep-seated fears.
I will serve as your confidante and companion.
I will hold your hand
Listen to your heart
And be fully present for you.
I pledge to cultivate your contentment
Joy
And peace of mind.
In all of this, I pray for your good health
And pledge my undying love for you
Now
And always
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article
The FDA flagged potential safety signals for colitis with Ibrance, Kisqali and Verzenio, and heart inflammation with melanoma drugs. No causal link is confirmed.
A biomarker test changed one mother’s diagnosis from suspected glioblastoma to ependymoma, but the report written in October did not reach her until December.
Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, from timeline to risks.
The approval adds patients with high-grade papillary-only tumors, based on trial data showing a 62% complete response rate in patients with carcinoma in situ.
The 2026 cancer report found U.S. cancer death rates continued to fall from 2019 to 2023, largely due to lung cancer progress, while diagnoses rose slightly among women.
Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.
Longer follow-up of the phase 2 LUNAR trial showed a 62% lower risk of progression, additional hormone therapy or death with 177Lu-PNT2002 plus radiation.
Advertisement
Advertisement
Trending on CURE
1
Radioligand Plus Radiation Delays Prostate Cancer Progression to 17.6 Months
2
FDA Expands Anktiva Approval in BCG-Unresponsive Bladder Cancer
3
What Is a Personalized Cancer Vaccine? What Patients Should Know
4
Anktiva for Papillary Bladder Cancer: What Patients Should Know
5